Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

HALE, G ; SLAVIN, S ; GOLDMAN, J. M ; MACKINNON, S ; GIRALT, S ; WALDMANN, H

Bone marrow transplantation (Basingstoke), 2002-12, Vol.30 (12), p.797-804 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível